Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults

In a dose-escalation study of the COVID-19 RNA vaccine BNT162b1 in 45 healthy adults, RBD-binding IgG concentrations and SARS-CoV-2 neutralizing titres in sera increased with dose level and after a second vaccine dose.

Read the full article here

Related Articles